<DOC>
	<DOCNO>NCT00458835</DOCNO>
	<brief_summary>The purpose study compare systemic des-ciclesonide exposure OMNARIS™ ( ciclesonide ) nasal spray , ciclesonide HFA nasal aerosol , orally inhaled ciclesonide HFA-metered-dose inhaler ( MDI ) . The administration study medication follow : three single dos , separate wash-out period . The study provide data safety tolerability ciclesonide .</brief_summary>
	<brief_title>Comparison Between Systemic Exposure Ciclesonide Nasal Spray , Ciclesonide HFA Nasal Aerosol Orally Inhaled Ciclesonide ( BY9010/M1-422 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Main Written inform consent HIPAA Body weight indicate Body Mass Index ( BMI ) ≥ 18 ≤ 28 kg/m² , body weight &gt; 50 kg General good health Ability use oral inhaler Main Pregnancy , breast feeding , intention become pregnant course study lack safe contraception premenopausal woman Participation investigational drug trial within 30 day Screening Visit thereafter History current clinically relevant allergy idiosyncrasy drug food History allergic reaction corticosteroid include ciclesonide excipients formulation Any contraindication nasally administered corticosteroid History respiratory infection disorder [ include , limited bronchitis , pneumonia , acute chronic sinusitis , flu , severe acute respiratory syndrome ( SARS ) ] within 30 day Screening Visit , development respiratory infection Screening Period History current evidence relevant allergic , cardiovascular , pulmonary , hepatic , renal , gastrointestinal , hematological , endocrine , metabolic , neurological , psychiatric , disease within last 2 year Nonvaccinated exposure active infection , chickenpox measles within 21 day precede Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Allergic rhinitis</keyword>
</DOC>